Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2014 / Cilt: 24 - Sayı: 3

Radyoterapi ile Eşzamanlı Trastuzumab Tedavisinden Sonra Verilen Hormonoterapinin Ciltte Gelişen Geç Toksisite Üzerine Etkisi

The Effects of Hormonotherapy Following Concomitant Use of Trastuzumab and Radiation Therapy on Late Skin Toxicity

Pages
163–170
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our study results suggested that tamoxifen and letrozole following concomitant use of T and RT increased skin fibrosis, while anastrazole and exemestane reduced radiation-induced skin fibrosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To investigate whether hormonotherapy followed by concomitant use of trastuzumab (T) and radiation therapy (RT) contributes to the development of radiation-induced skin fibrosis. 70 healthy female rats divided into seven groups: Control group (C) underwent no procedure.
📊
Key Findings & Data:Trastuzumab was administered in 6 mg/kg.
💡
Conclusion & Impact:Our study results suggested that tamoxifen and letrozole following concomitant use of T and RT increased skin fibrosis, while anastrazole and exemestane reduced radiation-induced skin fibrosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

To investigate whether hormonotherapy followed by concomitant use of trastuzumab (T) and radiation therapy (RT) contributes to the development of radiation-induced skin fibrosis. 70 healthy female rats divided into seven groups: Control group (C) underwent no procedure. RT group underwent thoracic radiation (TR). T group was administered T. T+RT+Tx group was administered concomitant T and TR, followed by tamoxifen. T+RT+Le group was administered concomitant T and TR, followed by letrozole. T+RT+An group was administered concomitant T and TR, followed by anastrazole. T+RT+Ex group was administered concomitant T and TR, followed by exemestane. Trastuzumab was administered in 6 mg/kg. TR was performed two hours after T administration. Hormonotherapy was given at one week following RT. Rats were sacrificed at 24 weeks. Skin was scored in histopathological examination. Skin inflammation was most commonly seen in the RT, T+RT+Tx and T+RT+Le group. Skin fibrosis was present in all subjects exposed to RT. Control group, T and T+RT+Ex group had the lowest vascular damage scores, while RT, T+RT+Tx and T+RT+Le had the highest scores. The RT, T+RT+Tx and T+RT+Le group had the highest muscular fibrosis scores. Muscular fibrosis was lesser in T+RT+An and T+RT+Ex group. The rate of vascular damage in muscular tissue was the highest in RT, T+RT+Tx and T+RT+Le group. No vascular damage was observed in T and T+RT+Ex group. Our study results suggested that tamoxifen and letrozole following concomitant use of T and RT increased skin fibrosis, while anastrazole and exemestane reduced radiation-induced skin fibrosis.

Özet

Radyoterapi ile eşzamanlı trastuzumab tedavisinden sonra verilen hormonoterapinin ciltte radyasyon fibrozisi gelişimine katkısı olup olmayacağını araştırmaktır. 70 adet erişkin sağlıklı sıçan, 7 gruba ayrıldı. K grup (Kontrol grubu); RT grubu (Sadece radyoterapi uygulanan); T grubu (Sadece trastuzumab verilen); T+RT+Tam grubu (RT ile eş zamanlı T verildikten sonra tamoksifen verilen grup); T+RT+Le grubu (RT ile eş zamanlı T sonrası letrozol verilen); T+RT+An grubu (RT ile eş zamanlı T sonrası anastrazol verilen); T+RT+Ex grubu (RT ile eşzamanlı T sonrası exemestan) verilen grup olarak belirlendi. Trastuzumab, 6 mg/kg verildi. RT, T’den iki saat sonra, göğüs duvarına tek fraksiyonda ışınlama yapıldı. RT’den bir hafta sonra hormonoterapi ilaçları 6 ay süre ile verildi. 24 hafta sonra sıçanlar sakrifiye edildi. Deri dokusu histopatolojik olarak incelendi. Deride inflemasyon en fazla RT, T+RT+Tam ve T+RT+Le gruplarında görüldü. RT alan grupların hepsinde deride fibrosizin oluştuğu görüldü. Deride vasküler hasar skorlaması en düşük kontrol, T ve T+RT+Ex gruplarında en yüksek skorlama RT, T+RT+Tam ve T+RT+Le gruplarında bulundu. Kasta fibrosiz skorlaması en yüksek RT, T, T+RT+Tam, T+RT+Le gruplarında bulundu. T+RT+An and T+RT+Ex gruplarında kasta fibrozisin azaldığı görüldü. Kasta vasküler hasarın en fazla RT, T+RT+Le ve T+RT+Tam gruplarında oluştuğu görüldü. T ve T+RT+Ex’nın ise hasar yapmadığı görüldü. RT ile eşzamanlı T kullanımından sonra ardışık uygulanan tamoksifen ve letrozolün ciltte fibrozisi artırdığı görüldü. Anastrazol ve exemestanın radyasyon fibrozisini azalttığı görüldü.

🔖

Cite This Article

CIHAN, Y. B., ARSAV, V. (2014). Radyoterapi ile Eşzamanlı Trastuzumab Tedavisinden Sonra Verilen Hormonoterapinin Ciltte Gelişen Geç Toksisite Üzerine Etkisi. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 24 - Sayı: 3, 163–170. https://ajindex.com/articles/322920

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. National Academies Press, Washington (DC), 2005: 250. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B- 31adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc ASCO 2007; 25: 512. Raj KA, Marks LB, Prosnitz RG. Late effects of breast radiotherapy in young women. Breast Dis 23: 53-65, 2005.
  2. Ertekin MV, Tekin SB, Erdogan F, et al. The effect of zinc sulphate in the prevention of radiation-induced dermatitis. J Rad Res 45: 543-548, 2004.
  3. Bernstein EF, Sullivan FJ, Mitchell JB, Salomon GD, Glatstein E. Biology of chronic radiation effect on tissues and wound healing. Clin Plast Surg 20: 435-453, 1993.
  4. Murakami R, Baba Y, Nishimura R, et al. The effect of azelastine on acute radiation dermatitis in mice models. J Rad Onc Biol Phys 37: 907-911, 1997.
  5. Bellon JR, Gover MT, Burnstein HJ. Concurrent trastuzumab and radiation therapy in the adjuvant treatment of breast cancer. Int J Radiat Oncol Biol Phys 63: 55-56, 2005.
  6. Belkacemi Y, Gligorov J, Ozsahin M, et al. Concurrent of trastuzumab with adjuvant radiotherapy in Her2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol 19: 1110–1116, 2008.
  7. Perez EA, Halyard A, Pisansky T, et al. Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER-2 positive breast cancer: cardiac safety data from the NCCTG N9831 study. Eur J Cancer Suppl 4: 113, 2006.
  8. Gallet P, Phulpin B, Merlim JL, et al. Long-term alterations of cytokines and growth factors expression in irradiated tissues and relation with histological severity scoring. PLoS One 6: e28399, 2011.
  9. Horton JK, Sherron RF, Moore DT, et al. Phase I/II trial of herceptin plus radiotherapyfor chemotherapy-refractory locally advanced or recurrent breast cancer. Int J of Radiat Oncol Biol Phys 66: 220-221, 2006.
  10. Koukourakis MI, Manavis J, Simopoulos C, et al. Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, doxorubicine, and doxataxel in cerbB-2-positive breast cancer. Am J Clin Oncol 28: 495-500, 2005.
  11. Valabrega G, Danese S, Vietti-Ramus G, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11: 318-324, 2006.
  12. Schmidt-Ulrich R, Wazer DE, Tercilla O, et al. Tumor margin assesment